Drug development targeting the glycogen synthase kinase-3/β (GSK-3/β)-mediated signal transduction pathway: Inhibitors of the Wnt//β-catenin signaling pathway as novel anticancer drugs

Journal of Pharmacological Sciences

Volumn 109, Issue 2, 2009, Pages 179-183

  Takahashi Yanaga, Fumi ^a   Sasaguri, Toshiyuki ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Cancer; Differentiation inducing factor; Drug development; Glycogen synthase kinase 3 (GSK 3 ); Wnt catenin signaling

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; CYCLIN D1; DIFFERENTIATION INDUCING FACTOR; DIFFERENTIATION INDUCING FACTOR 1; DIFFERENTIATION INDUCING FACTOR 3; FRIZZLED PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; UNCLASSIFIED DRUG; WNT PROTEIN; ALKANONE; CHLORINATED HYDROCARBON; DIFFERENTIATION INDUCING FACTOR 1, DICTYOSTELIUM; DIFFERENTIATION-INDUCING FACTOR-1, DICTYOSTELIUM; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CARCINOGENESIS; CELL CYCLE ARREST; CELL DIFFERENTIATION; DICTYOSTELIUM DISCOIDEUM; DRUG EFFECT; DRUG TARGETING; ENZYME ACTIVATION; HUMAN; NONHUMAN; PROTEIN PHOSPHORYLATION; SHORT SURVEY; SIGNAL TRANSDUCTION; ANIMAL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; METABOLISM; MOUSE; PHYSIOLOGY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; BETA CATENIN; CYCLIN D1; DRUG DELIVERY SYSTEMS; GLYCOGEN SYNTHASE KINASE 3; HEXANONES; HUMANS; HYDROCARBONS, CHLORINATED; MICE; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 65449133183     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08R28FM     Document Type: Short Survey

References (35)

1. Nelson WJ, Nusse R. Convergence of Wnt, β-catenin, and cadherin pathways. Science. 2004;303:1483-1487.
2. Moon RT, Bowerman B, Boutros M, Perrimon N. The promise and perils of Wnt signaling through β-catenin. Science. 2002; 296:1644-1646.
3. Akiyama T. Wnt/β-catenin signaling. Cytokine Growth Factor Rev. 2000;11:273-282.
4. Mlodzik M. Planar cell polarization: do the same mechanisms regulate Drosophila tissue polarity and vertebrate gastrulation? Trends Genet. 2002;18:564-571.
5. Kiihl M, Sheldahl LC, Park M, Miller JR, Moon RT. The Wnt/Ca2+ pathway: a new vertebrate Wnt signaling pathway takes shape. Trends Genet. 2000;16:279-283.
6. Chen AE, Ginty DD, Fan CM. Protein kinase A signalling via CREB controls myogenesis induced by Wnt proteins. Nature. 2005;433:317-322.
7. Cohen P, Frame S. The renaissance of GSK3. Nat Rev Mol Cell Biol. 2001;2:769-776.
8. Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J. 2001;359:1-16.
9. Cross D, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378:785-789.
10. Kitagawa M, Hatakeyama S, Shirane M, Matsumoto M, Ishida N, Hattori K, et al. An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of β-catenin. EMBO J. 1999;18: 2401-2410.
11. Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, et al. Control of β-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell. 2002;108:837-847.
12. Willert K, Jones KA. Wnt signaling: is the party in the nucleus? Genes Dev. 2006;20:1394-1404.
13. Sherr CJ. D-type cyclins. Trends Biochem Sci. 1995;20:187-190.
14. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672-1677.
15. Barnes DM, Gillett CE. Cyclin D1 in breast cancer. Brest Cancer Res Treat. 1998;52:1-15.
16. Barbieri F, Lorenzi P, Ragni N, Schettini G, Bruzzo C, Pedulla F, et al. Overexpression of cyclin D1 is associated with poor survival in epithelial ovarian cancer. Oncology. 2004;66:310-315.
17. Utsunomiya T, Doki Y, Takemoto H, Shiozaki H, Yano M, Sekimoto M, et al. Correlation of β-catenin and cyclin D1 expression in colon cancers. Oncology. 2001;61:226-233.
18. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Cyclin D1: normal and abnormal functions. Endocrinology. 2004;145:5439-5447.
19. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer. 2001;1:222-231.
20. Diehl JA, Zindy F, Sherr CJ. Inhibition of cyclin D1 phosphory-lation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev. 1997;11:957-972.
21. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998;12:3499-3511.
22. Alt JR, Cleveland JL, Hannink M, Diehl JA. Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1- dependent cellular transformation. Genes Dev. 2000;15:3102-3114.
23. Morris HR, Taylor GW, Masento MS, Jermyn KA, Kay RR. Chemical structure of the morphogen differentiation inducing factor from Dictyostelium discoideum. Nature. 1987;328:811-814.
24. Morris HR, Masento MS, Taylor GW, Jermyn KA, Kay RR. Structure elucidation of two differentiation inducing factors (DIF-2 and DIF-3) from the cellular slime mould Dictyostelium discoideum. Biochem J. 1988;249:903-906.
25. Asahi K, Sakurai A, Takahashi N, Kubohara Y, Okamoto K, Tanaka Y. DIF-1, morphogen of Dictyostelium discoideum, induces the erythroid differentiation in murine and human leukemia cells. Biochem Biophys Res Commun. 1995;208: 1036-1039.
26. Kubohara Y. DIF-1, putative morphogen of D. discoideum, suppresses cell growth and promotes retinoic acid-induced cell differentiation in HL-60. Biochem Biophys Res Commun. 1997;236:418-422.
27. Kubohara Y. Effects of differentiation-inducing factors of Dictyostelium discoideum on human leukemia K562 cells: DIF-3 is the most potent anti-leukemic agent. Eur J Pharmacol. 1999;381:57-62.
28. Takahashi-Yanaga F, Taba Y, Miwa Y, Kubohara Y, Watanabe Y, Hirata M, et al. Dictyostelium differentiation-inducing factor-3 activates glycogen synthase kinase-3β and degrades cyclin D1 in mammalian cells. J Biol Chem. 2003;278:9663-9670.
29. Yasmin T, Takahashi-Yanaga F, Mori J, Miwa Y, Hirata M, Watanabe Y, et al. Differentiation-inducing factor-1 suppresses gene expression of cyclin D1 in tumor cells. Biochem Biophys Res Commun. 2005;338:903-909.
30. Mori J, Takahashi-Yanaga F, Miwa Y, Watanabe Y, Hirata M, Morimoto S, et al. Differentiation-inducing factor-1 induces cyclin D1 degradation through the phosphorylation of Thr286 in squamous cell carcinoma. Exp Cell Res. 2005;310:426-433.
31. Takahashi-Yanaga F, Mori J, Matsuzaki E, Watanabe Y, Hirata M, Miwa Y, et al. Involvement of GSK-3β and DYRK1B in differentiation-inducing factor-3-induced phosphorylation of cyclin D1 in HeLa cells. J Biol Chem. 2006;281:38489-38497.
32. Zou Y, Ewton DZ, Deng X, Mercer SE, Friedman E. Mirk/dyrk1B kinase destabilizes cyclin D1 by phosphorylation at threonine 288. J Biol Chem. 2004;279:27790-27798.
33. Shimizu K, Murata T, Tagawa T, Takahashi K, Ishikawa R, Abe Y, et al. Calmodulin-dependent cyclic nucleotide phospho-diesterase (PDE1) is a pharmacological target of differentiation-inducing factor-1, an antitumor agent isolated from Dictyostelium. Cancer Res. 2004;64:2568-2571.
34. Kakkar R, Raju RV, Sharma RK. Calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1). Cell Mol Life Sci. 1999; 55:1164-1186.
35. Lerner A, Kim DH, Lee R. The cAMP signaling pathway as a therapeutic target in lymphoid malignancies. Leuk Lymphoma. 2000;37:39-51.